Brain Center Rudolf Magnus is the research body of ‘UMC Utrecht Hersencentrum’. Our mission is to perform high-level research in clinical and experimental neuroscience, whilst delivering an exceptional standard of care.
Prof. dr René Kahn is Professor and Chair of the Department of Psychiatry and Head of the Division of Neuroscience at the University Medical Center, Utrecht, The Netherlands. His current research interests include neuroimaging in schizophrenia and the genetic dissection of complex traits in specific psychiatric disorders.
Our researchers in the area of Stroke work to identify genetic and environmental risk factors that determine vulnerability in patients. We also search for novel treatments to aid in recovery post-stroke. Practitioners, starting at the bedside, directly carry much of our research out.
The Epilepsy research team uses multiple approaches to uncover the complex interplay between genetic and environmental factors that contribute to the development of refractory epilepsy. Through this approach, we work toward finding novel treatment options for refractory Epilepsy in children and adults.
Within the research team Neuromuscular Disorders, we face deeply complex and challenging questions. Hand in hand with our patients, we unravel the disease mechanisms of these disorders, our aim is to deliver effective treatments, quickly. Our approach is characterized by intense interactions between clinical and preclinical investigators.
Our research team focuses on unraveling the mechanisms that underlie psychotic disorders. We strive toward developing new clinical assessments and treatments, and draw on all approaches to further our understanding of the intersection between biological and psychosocial factors.
The team of researchers in the area of Developmental Disorders are building on UMC Utrecht’s long history in research of developmental disorders such as ADHD and autism. We utilize advanced clinical diagnostic tools that combined with genetic approaches, neuroimaging and cognitive psychology help to uncover the developmental, neurobiological pathways underlying complex developmental disorders.
In a joint venture with Philips Medical Systems -and supported by Utrecht University, the UMC Utrecht and the Netherlands Organisation for Scientific Research-, a 7T brain scanner was implemented at the UMC Utrecht in 2007. Since then Peter Luijten and his team of MR physicists, radiologists and neuroscientists has continuously improved hardware and software of the scanner. Today, this scanner is among the best-functioning 7T scanners worldwide and already used for clinical purposes.
Nick Ramsey runs a lab where the latest developments in imaging brain activity, machine learning techniques and microsystems technology merge. His team of engineers, fMRI-experts and cognitive neuroscientists work on two major projects, at least until 2018. The first: putting years of technical innovation to the test, trying to enable five paralyzed patients to operate a computer with their thoughts, in the Utrecht Neural Prosthesis (UNP) project.
The second project is called iCONNECT, for which Ramsey received a personal ERC Advanced grant of 2.5 million Euro. In iCONNECT, Ramsey’s group explores brain patterns and develops decoding strategies, using 7 Tesla MRI and electrocorticography. The aim is a brain computer interface-system that interprets activity patterns on the surface of the brain, in real-time.
UMC Utrecht Brain Center Rudolf Magnus
3584 CG Utrecht
This April, the European commission has awarded an Horizon 2020 grant sized almost € 6 million to the project PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. The project will be coordinated by neurologist Bart van der Worp and includes a pragmatic, randomised, clinical trial in 3800 elderly patients with acute stroke. Elderly patients are at high risk of complications after stroke, such as infections, fever, and dysphagia. These complications are strongly and independently associated with a higher risk of death or long-term dependency. PRECIOUS will assess whether pharmacological prevention of infections and fever, and early management of dysphagia, will reduce the risk of death, poor functional outcome, and poor quality of life, and lead to reductions in the costs of stroke care throughout Europe. Patients will be enrolled in 80 centres in 9 European countries and randomised using a factorial design to preventive treatment for 4 days with ceftriaxone, paracetamol, and/or metoclopramide, or to ‘standard care’ alone. The primary outcome measure is functional outcome at 3 months. The simple, safe, and generally available treatment strategies tested in PRECIOUS have the potential to lead to an annual reduction of over 25 000 elderly Europeans being dead or dependent as a result of stroke, at very low costs.